Real-life Data of Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients: A Single-center Study

Basit Öğe Kaydı
dc.authoridcabalak, mehmet/0000-0003-1148-2247
dc.contributor.authorCabalak, Mehmet
dc.contributor.authorBal, Tayibe
dc.contributor.authorOcak, Sabahattin
dc.contributor.authorBal, Isa Ahmet
dc.contributor.authorOnlen, Yusuf
dc.date.accessioned2024-09-18T20:55:41Z
dc.date.available2024-09-18T20:55:41Z
dc.date.issued2023
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractBackground: Glecaprevir/pibrentasvir (G/P) is a pangenotypic direct-acting antiviral (DAA) drug with a high resistance barrier. It has been used in patients with chronic hepatitis C in Turkey since March 2019. This drug's efficacy and safety data in Turkey are very limited, and there are not enough studies on real-life data.Objectives: In this study, we aim to present real-life data, efficacy, and safety for our patients. Methods: In this retrospective, observational, single-center study, 116 patients who were started on G/P (100mg/40mg) oral therapy at the infectious diseases clinic between March 2019 and December 2021 due to HCV were included. Of the 116 patients included in the study, 92 were analyzed. Demographic data of the patients, previous treatment experience, drug use, viral load (HCV RNA levels at the 4th week of treatment and 12th week after treatment), and viral genotype data were obtained retrospectively from the automation system. Statistical analysis IBM SPSS version 21.0 statistical package program was used.Results: Seventy-one (77.2%) of the patients were male, and 21 (22.8%) were female, with a mean age of 47.4 (18 -89). Genotype dis-tribution of patients 8.7% (n = 8) type 1a, 31.5% (n = 29) type 1b, 26.1% (n = 24) type 2, 22.9% (n = 21) type 3,10.9% (n = 10) were type 4, 8.7% (n = 8) of the patients were treatment-experienced. In our study, there were no patients with cirrhosis. SVR-12 could not be obtained from a patient infected with only genotype 1a. In addition, this patient was co-infected with Hepatitis B. No side effects were observed in any of the patients that required treatment discontinuation. The SVR-12 rate was 98.6% with patients per protocol analysis (PP), but the SVR-12 rate was 77.2% with intention to treat analysis (ITT).Conclusions: In conclusion, this study suggested that G/P therapy in Turkey is used in real life with very high efficacy and tolerability. In addition, a significant change was observed in the genotype distribution previously reported in Turkey in the patient group we treated.en_US
dc.identifier.doi10.5812/hepatmon-134406
dc.identifier.issn1735-143X
dc.identifier.issn1735-3408
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85158104768en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.5812/hepatmon-134406
dc.identifier.urihttps://hdl.handle.net/20.500.12483/11996
dc.identifier.volume23en_US
dc.identifier.wosWOS:001045843200008en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherBrieflanden_US
dc.relation.ispartofHepatitis Monthlyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectReal -life Dataen_US
dc.subjectChronic HCV Hepatitisen_US
dc.subjectGlecapreviren_US
dc.subjectPibrentasvir (GLEen_US
dc.subjectPIB)en_US
dc.titleReal-life Data of Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients: A Single-center Studyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text
Boyut:
464.15 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu